Answers are grounded in this paper and cite their sources.
To the Editor: Ependymomas (EPNs) are one of the major central nervous system tumors in children, accounting for approximately 5%.1 Histologically, they exhibit both glial and epithelial features. Supratentorial ependymomas (ST-EPNs) constitute 25%-35% of cases and are well recognized for harboring characteristic fusion genes. The majority of fusion-positive ST-EPNs carry ZFTA fusions; these are associated with a higher risk of metastasis and 5-year overall survival (OS) rates of approximately 75%-85%.2,3 In contrast, ST-EPN with YAP1 fusions (ST-EPN-YAP1) are associated with excellent prognosis with reported 5-year OS rates approaching 100%.2,3 Among the ST-EPN-YAP1, the most well-known subtype is YAP1::MAMLD1,4 while YAP1::FAM118B is observed in some cases.5 TEAD1::NCOA2 has also been reported recently.6 In adult ST-EPN7 and pediatric posterior fossa EPN (PF-EPN),8 the rare fusion gene YAP1::MAML2 has been described. Here, we report the first case of pediatric ST-EPN harboring a YAP1::MAML2 fusion, in which the detection of this fusion was helpful for diagnosis and treatment planning. We also present an integrated analysis of DNA methylation profiles from this case and a previously reported YAP1::MAML2 fusion-positive ST-EPN.
No takes yet. Share an insight, caveat, or question.
Kawata et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: